Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02521051 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02521051: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02521051 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02521051, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
Interventions
- DRUG Bevacizumab
- DRUG Alectinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2022-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02521051
The ClinicalTrials.gov registry entry for NCT02521051 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02521051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02521051 about?
NCT02521051 is a clinical study titled "Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer". This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
What is the current status of trial NCT02521051?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-09-28. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02521051?
The interventions under investigation include: Bevacizumab (DRUG), Alectinib (DRUG).
Who is sponsoring clinical trial NCT02521051?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.